{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:05:26Z","timestamp":1775153126369,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.medj.2024.07.029","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T11:37:19Z","timestamp":1731065839000},"page":"1335-1337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual epigenetic therapy plus chemotherapy in peripheral T\u00a0cell lymphoma with T follicular helper phenotype"],"prefix":"10.1016","volume":"5","author":[{"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2024.07.029_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.medj.2024.07.007","article-title":"A prospective phase 2 study of combination epigenetic therapy against relapsed\/refractory peripheral T\u00a0cell lymphoma","volume":"4","author":"Ding","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.medj.2024.07.029_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.clml.2022.04.015","article-title":"Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma","volume":"22","author":"Atallah-Yunes","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.medj.2024.07.029_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.medj.2024.07.029_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.medj.2024.07.029_bib5","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2024.07.029_bib6","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2024.07.029_bib7","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.3324\/haematol.2018.187617","article-title":"A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral\u00a0T-cell lymphoma","volume":"103","author":"Strati","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.medj.2024.07.029_bib8","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.medj.2024.07.029_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2021-145495","article-title":"High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study","volume":"138","author":"Ruan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.medj.2024.07.029_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2023-179304","article-title":"Efficacy and Safety of Valemetostat Monotherapy in patients with relapsed or refractory peripheral T-Cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 study","volume":"142","author":"Horwitz","year":"2023","journal-title":"Blood"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634024003118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:39:35Z","timestamp":1773830375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634024003118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666634024003118"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2024.07.029","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual epigenetic therapy plus chemotherapy in peripheral T\u00a0cell lymphoma with T follicular helper phenotype","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2024.07.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}